Princeton Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Princeton Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-450	Closed	-$43K	–	95
2022 Q3	$43K	Hold	450	–	–	0.02%	89
2022 Q2	$88K	Sell	450 -16	-3%	-$2.61K	0.03%	94
2022 Q1	$108K	Hold	466	–	–	0.03%	108
2021 Q4	$184K	Sell	466 -18	-4%	-$7.58K	0.05%	111
2021 Q3	$216K	Buy	484 +19	+4%	+$6.81K	0.07%	104
2021 Q2	$181K	Buy	465 +24	+5%	+$8.56K	0.06%	105
2021 Q1	$158K	Hold	441	–	–	0.05%	100
2020 Q4	$216K	Sell	441 -102	-19%	-$47.1K	0.08%	98
2020 Q3	$176K	Hold	543	–	–	0.07%	92
2020 Q2	$198K	Buy	+543	New	+$137K	0.09%	91
2019 Q4	–	Sell	-181	Closed	-$64K	–	102
2019 Q3	$64K	Buy	181 +88	+95%	+$32.8K	0.03%	139
2019 Q2	$47K	Buy	+93	New	+$65.6K	0.02%	154

Other funds holding ATRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Princeton Capital Management's ATRA Position: Q4 2022 in Review

Princeton Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 450 shares — an estimated $43K sold.

Princeton Capital Management first reported a position in ATRA in Q2 2019 and held it in 12 quarters. The position peaked at $216K in Q3 2021. 138 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

Princeton Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Princeton Capital Management sold 450 Atara Biotherapeutics shares in Q4 2022, an estimated $43K.
Princeton Capital Management first reported a position in Atara Biotherapeutics in Q2 2019 and held it in 12 quarters.
Princeton Capital Management's Atara Biotherapeutics position peaked at $216K in Q3 2021.
138 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Princeton Capital Management's 13F filing for Q4 2022, filed 31 Jan 2023.